Blab Tech
Ultrahuman Launches M2 Live: Affordable Continuous Glucose Monitoring for Non-Diabetic Adults
Ultrahuman, a U.S. health‑tech company, has announced the launch of its new M2 Live platform, a continuous glucose monitoring (CGM) service that does not require a prescription and is aimed at adults who are not on insulin. The platform uses Abbott’s Lingo CGM sensor and is available in the United States beginning in the coming weeks.
The M2 Live system combines a 14‑day Lingo sensor with the Ultrahuman mobile app. According to the company’s website, the sensor costs $129 when purchased through Ultrahuman, while the sensor itself is sold by Abbott for $49 on Amazon. The platform is offered with a $99 monthly subscription, although some reports suggest that the service can be accessed without a subscription if the user does not own an Ultrahuman Ring.
Key features of the M2 Live platform are:
Metabolic Score – The app translates glucose patterns into a daily score ranging from 0 to 100. The score is calculated from glucose variability, average glucose, and time spent in target ranges. Glucose Alerts – The app streams data from the Lingo sensor and notifies users when glucose spikes exceed preset thresholds. Food Score – Each meal is assigned a rating between 1 and 10 based on the user’s glucose response, providing a simple way to compare foods over time. Connected Health Context – Data from the Ultrahuman Ring Air—sleep, heart‑rate variability (HRV), activity, recovery, and skin temperature—is integrated to help explain glucose fluctuations. * Workout Fuel Insights – The Fueling Score shows how glucose availability relates to exercise output, endurance, and recovery.
The Lingo sensor is a minimally invasive electrochemical CGM that attaches to the back of the upper arm. It measures interstitial glucose, which correlates strongly with blood glucose, and transmits readings via Bluetooth to the Ultrahuman app. The sensor is intended for adults 18 years and older who are not on insulin and does not require calibration.
Ultrahuman’s M2 Live follows the company’s earlier M1 Live platform, which was priced at $249 per month. The new platform is positioned as a more affordable option for users who want continuous glucose data without a prescription or a separate wearable device. The company’s marketing materials emphasize that the system is a practical tool for anyone interested in metabolic feedback.
The launch of M2 Live reflects a broader trend in which CGM technology, traditionally used for diabetes management, is being adopted by non‑diabetic consumers. According to industry reports, CGMs are now popular among people with pre‑diabetes, athletes, and health‑conscious individuals who want to track dietary responses and weight‑management strategies.
The Ultrahuman Ring Air, which accompanies the M2 Live platform, tracks sleep stages, HRV, movement, and skin temperature. The ring’s data is used by the app to provide context for glucose readings, helping users understand how sleep quality or stress levels may influence metabolic health.
While the M2 Live platform is available only in the United States, the company has stated that it plans to expand to other markets in the future. The platform’s pricing structure—$129 for a 14‑day sensor and $99 per month for the service—makes it one of the most affordable CGM options for non‑diabetic adults.
In summary, Ultrahuman’s M2 Live offers continuous glucose monitoring through Abbott’s Lingo sensor, paired with a suite of metrics that translate glucose data into actionable insights. The system is designed for adults 18 and older who are not on insulin, does not require a prescription, and is available in the U.S. with a monthly subscription fee. The platform’s integration with the Ultrahuman Ring Air provides additional context for glucose fluctuations, making it a comprehensive tool for metabolic tracking.
The product’s launch is part of a growing movement toward consumer‑centric health monitoring, and it remains to be seen how widely it will be adopted outside the United States. The company’s next steps include monitoring user engagement, refining the scoring algorithms, and exploring regulatory approvals for broader distribution.
The M2 Live system combines a 14‑day Lingo sensor with the Ultrahuman mobile app. According to the company’s website, the sensor costs $129 when purchased through Ultrahuman, while the sensor itself is sold by Abbott for $49 on Amazon. The platform is offered with a $99 monthly subscription, although some reports suggest that the service can be accessed without a subscription if the user does not own an Ultrahuman Ring.
Key features of the M2 Live platform are:
Metabolic Score – The app translates glucose patterns into a daily score ranging from 0 to 100. The score is calculated from glucose variability, average glucose, and time spent in target ranges. Glucose Alerts – The app streams data from the Lingo sensor and notifies users when glucose spikes exceed preset thresholds. Food Score – Each meal is assigned a rating between 1 and 10 based on the user’s glucose response, providing a simple way to compare foods over time. Connected Health Context – Data from the Ultrahuman Ring Air—sleep, heart‑rate variability (HRV), activity, recovery, and skin temperature—is integrated to help explain glucose fluctuations. * Workout Fuel Insights – The Fueling Score shows how glucose availability relates to exercise output, endurance, and recovery.
The Lingo sensor is a minimally invasive electrochemical CGM that attaches to the back of the upper arm. It measures interstitial glucose, which correlates strongly with blood glucose, and transmits readings via Bluetooth to the Ultrahuman app. The sensor is intended for adults 18 years and older who are not on insulin and does not require calibration.
Ultrahuman’s M2 Live follows the company’s earlier M1 Live platform, which was priced at $249 per month. The new platform is positioned as a more affordable option for users who want continuous glucose data without a prescription or a separate wearable device. The company’s marketing materials emphasize that the system is a practical tool for anyone interested in metabolic feedback.
The launch of M2 Live reflects a broader trend in which CGM technology, traditionally used for diabetes management, is being adopted by non‑diabetic consumers. According to industry reports, CGMs are now popular among people with pre‑diabetes, athletes, and health‑conscious individuals who want to track dietary responses and weight‑management strategies.
The Ultrahuman Ring Air, which accompanies the M2 Live platform, tracks sleep stages, HRV, movement, and skin temperature. The ring’s data is used by the app to provide context for glucose readings, helping users understand how sleep quality or stress levels may influence metabolic health.
While the M2 Live platform is available only in the United States, the company has stated that it plans to expand to other markets in the future. The platform’s pricing structure—$129 for a 14‑day sensor and $99 per month for the service—makes it one of the most affordable CGM options for non‑diabetic adults.
In summary, Ultrahuman’s M2 Live offers continuous glucose monitoring through Abbott’s Lingo sensor, paired with a suite of metrics that translate glucose data into actionable insights. The system is designed for adults 18 and older who are not on insulin, does not require a prescription, and is available in the U.S. with a monthly subscription fee. The platform’s integration with the Ultrahuman Ring Air provides additional context for glucose fluctuations, making it a comprehensive tool for metabolic tracking.
The product’s launch is part of a growing movement toward consumer‑centric health monitoring, and it remains to be seen how widely it will be adopted outside the United States. The company’s next steps include monitoring user engagement, refining the scoring algorithms, and exploring regulatory approvals for broader distribution.
